DentalCare Logo

Adverse Drug Reactions - Part II

Course Number: 537

PDF

References / Additional Resources

  1. Conner MW, Dorian-Conner C, Vaidya VS, et al. Drug toxicity - Principles of pharmacology: The pathophysiologic basis of drug therapy, 4th edition. David E. Golan (Ed). Philadelphia, PA. Wolters Kluwer. 2017. 70-86.

  2. Williams KA, Taifour ML, Huber MA. Adverse Drug Reactions - Part I. dentalcare.com. Accessed January 15, 2023.

  3. Riedl MA, Casillas AM. Adverse drug reactions: types and treatment options. Am Fam Physician. 2003 Nov 1;68(9):1781-90.

  4. Belle DJ, Singh H. Genetic factors in drug metabolism. Am Fam Physician. 2008 Jun 1;77(11):1553-60.

  5. Dahlin A, Tantisira K. Pharmacogenomics - Principles of pharmacology: The pathophysiologic basis of drug therapy, 4th edition. David E. Golan (Ed). Philadelphia, PA. Wolters Kluwer. 2017. 87-95.

  6. Krump NA, You J. Molecular mechanisms of viral oncogenesis in humans. Nat Rev Microbiol. 2018 Nov;16(11):684-698.

  7. Valladares DA, Rasmussen SA. An update on teratogens for pediatric healthcare providers. Curr Opin Pediatr. 2022 Dec 1;34(6):565-571.

  8. Council for International Organizations for Medical Sciences. Reporting adverse drug reactions. Definitions of terms and criteria for their use. Geneva. CIOMS. 2000. Accessed January 15, 2023

  9. Roswarski M, Villa KR, Kiersma ME, et al. Prevalence of Adverse Drug Effects/Adverse Drug Reactions in 200 Most Commonly Prescribed Drugs Corrected for Prescription Volume. Purdue University, School of Pharmacy and Pharmaceutical Sciences, West Lafayette, IN. Accessed January 15, 2023.

  10. National Institute of Health. U.S. National Library of Medicine. DailyMed. Accessed January 15, 2023.

  11. Kumar K, Singh SI. Neuraxial opioid-induced pruritus: An update. J Anaesthesiol Clin Pharmacol. 2013 Jul-Sep; 29(3): 303–307. doi: 10.4103/0970-9185.117045

  12. Radonjic-Hoesli S, Hofmeier KS, Micaletto S, et al. Urticaria and Angioedema: an Update on Classification and Pathogenesis. Clin Rev Allergy Immunol. 2018 Feb;54(1):88-101.  

  13. Fernandez J. Angioedema. Merck Manual Professional Version. Accessed January 15, 2023.

  14. Samim F, Auluck A, Zed C, Williams PM. Erythema multiforme: a review of epidemiology, pathogenesis, clinical features, and treatment. Dent Clin North Am. 2013 Oct;57(4):583-96.

  15. Jacobsen PL, Chávez EM. Clinical management of the dental patient taking multiple drugs. J Contemp Dent Pract. 2005 Nov 15;6(4):144-51.

  16. Fernandez J. Overview of Allergic and Atopic Disorders. Merck Manual Professional Version. Accessed January 15, 2023.

  17. Yuan A, Woo SB. Adverse drug events in the oral cavity. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015 Jan;119(1):35-47.

  18. Adwan MH. An update on drug-induced arthritis. Rheumatol Int. 2016 Aug;36(8):1089-97.

  19. Rixe N, Tavarez MM. Serum Sickness. [Updated 2022 Aug 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Accessed January 15, 2023

  20. Gasche Y, Daali Y, Fathi M, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med. 2004 Dec 30;351(27):2827-31. Accessed January 15, 2023.

  21. US National Library of Medicine. DailyMed. MINOCIN- minocycline hydrochloride capsule, coated pellets. Accessed January 15, 2023.

  22. US National Library of Medicine. DailyMed. DOXYCYCLINE capsule. Accessed January 15, 2023.

  23. Czeizel AE, Rockenbauer M. A population-based case-control teratologic study of oral oxytetracycline treatment during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2000 Jan;88(1):27-33.

  24. Alemany S, Avella-García C, Liew Z, et al. Prenatal and postnatal exposure to acetaminophen in relation to autism spectrum and attention-deficit and hyperactivity symptoms in childhood: Meta-analysis in six European population-based cohorts. Eur J Epidemiol. 2021 Oct;36(10):993-1004.

  25. Baker BH, Lugo-Candelas C, Wu H, et al. Association of Prenatal Acetaminophen Exposure Measured in Meconium With Risk of Attention-Deficit/Hyperactivity Disorder Mediated by Frontoparietal Network Brain Connectivity. JAMA Pediatr. 2020 Nov 1;174(11):1073-1081.

  26. Dosi TR, Chawla AK, Barkalle G, Phulambrikar T. Herpes zoster of orofacial region. J Oral Maxillofac Pathol. 2021 Sep-Dec;25(3):557.

  27. Slots J, Saygun I, Sabeti M, Kubar A. Epstein-Barr virus in oral diseases. J Periodontal Res. 2006 Aug;41(4):235-44.

  28. Scully C, Bagan JV. Adverse drug reactions in the orofacial region. Crit Rev Oral Biol Med. 2004 Jul 1;15(4):221-39.

  29. American Addiction Centers. Drug Withdrawal Symptoms, Timelines & Treatment. Accessed January 15, 2023.

  30. Lockhart PB, Tampi MP, Abt E, et al. Evidence-based clinical practice guideline on antibiotic use for the urgent management of pulpal- and periapical-related dental pain and intraoral swelling: A report from the American Dental Association. J Am Dent Assoc. 2019 Nov;150(11):906-921.

  31. Scott IA, Le Couteur DG. Physicians need to take the lead in deprescribing. Intern Med J. 2015 Mar;45(3):352-6.

  32. Stein K, Farmer J, Singhal S, et al. The use and misuse of antibiotics in dentistry: A scoping review. J Am Dent Assoc. 2018 Oct;149(10):869-884.

  33. Thornhill MH, Suda KJ, Durkin MJ, Lockhart PB. Is it time US dentistry ended its opioid dependence? J Am Dent Assoc. 2019 Oct;150(10):883-889.

  34. Tomczyk S, Whitten T, Holzbauer SM, Lynfield R. Combating antibiotic resistance: a survey on the antibiotic-prescribing habits of dentists. Gen Dent. 2018 Sep-Oct;66(5):61-68.

  35. Davis TC, Federman AD, Bass PF 3rd, et al. Improving patient understanding of prescription drug label instructions. J Gen Intern Med. 2009 Jan;24(1):57-62.

  36. National Academies of Sciences, Engineering, and Medicine. 2017. Communicating clearly about medicines: Proceedings of a workshop. Washington, DC: The National Academies Press. doi:

  37. Sears K, Beigi P, Niyyati SS, Egan R. Patient-Related Risk Factors for the Occurrence of Patient-Reported Medication Errors in One Community Pharmacy: A Local Perspective. J Pharm Technol. 2016 Feb;32(1):3-8.

  38. U.S. Department of Health and Human Services. U.S. Food and Drug Administration. Safety. MedWatch. The FDA Safety Information and Adverse Event Reporting Program. Reporting Serious Problems to FDA. Instructions for Completing Form FDA 3500. Accessed January 15, 2023.

Additional Resources


  • No Additional Resources Available
0/18Next